Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 10/20 | 0.71 |
| ▸ | SRD5A1 | P18405 | 10/20 | 0.71 |
| ▸ | USP2 | O75604 | 2/20 | 0.67 |
| ▸ | RORA | P35398 | 3/20 | 0.58 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.58 |
| ▸ | RORC | P51449 | 2/20 | 0.58 |
| ▸ | GPR183 | P32249 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.51 |
| ▸ | FNTB | P49356 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8582643 | 0.89 | USP2 (0.63) | SRD5A2SRD5A1USP2RORANPC1L1 | |
| SCHEMBL8931526 | 0.89 | USP2 (0.63) | SRD5A2SRD5A1USP2RORANPC1L1 | |
| SCHEMBL30653764 | 0.89 | GPR183 (0.74) | SRD5A2SRD5A1USP2RORANPC1L1 | |
| SCHEMBL21449281 | 0.89 | GPR183 (0.74) | SRD5A2SRD5A1USP2RORANPC1L1 | |
| SCHEMBL8331946 | 0.89 | SRD5A1 (0.72) | SRD5A2SRD5A1USP2RORANPC1L1 | |
| SCHEMBL10066862 | 0.85 | GPR183 (0.80) | SRD5A2SRD5A1USP2RORANPC1L1 | |
| SCHEMBL8332687 | 0.83 | SRD5A2 (1.00) | SRD5A2SRD5A1USP2RORANPC1L1 | |
| SCHEMBL917735 | 0.83 | SRD5A2 (1.00) | SRD5A2SRD5A1USP2RORANPC1L1 | |
| SCHEMBL8335344 | 0.83 | SRD5A2 (1.00) | SRD5A2SRD5A1RORANPC1L1RORC | |
| SCHEMBL916778 | 0.83 | SRD5A2 (1.00) | SRD5A2SRD5A1RORANPC1L1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0786999-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0572165-B1 | New 7B-substituted-4-aza-5a-cholestan-ones as 5a-reductase inhibitors | MERCK & CO INC (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | disclosed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | disclosed |
| US-5527807-A | TREATING ALOPECIA, ACNE, PROSTATE DISORDERS | MERCK & CO., INC. (US) | 1996-06-18 | — | — | US | disclosed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1995013815-A1 | COMBINATION METHOD FOR THE TREATMENT OF PATTERNED ALOPECIA | MERCK & CO., INC. (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995013077-A1 | 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-3-ONES AS SELECTIVE 5α-REDUCTASE 1 INHIBITORS | MERCK & CO., INC. (US) | 1995-05-18 | — | — | WO | disclosed |
| EP-0572165-A1 | New 7B-substituted-4-aza-5a-cholestan-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | disclosed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |